Mutant interleukin-2 polypeptides
First Claim
1. An immunoconjugate comprising a mutant interleukin-2 (IL-2) polypeptide and an immunoglobulin molecule that specifically binds Fibroblast Activation Protein (FAP), wherein said mutant IL-2 polypeptide comprises a mutant form of SEQ ID NO:
- 1, wherein said mutant form of SEQ ID NO;
1 comprises up to five amino acid substitutions of SEQ ID NO;
1, wherein said up to five amino acid substitutions comprise;
alanine at amino acid residue 42 of SEQ ID NO;
1, alanine at amino acid residue 45 of SEQ ID NO;
1, and glycine at amino acid residue 72 of SEQ ID NO;
1; and
wherein said immunoglobulin molecule comprises a heavy chain variable region sequence of SEQ ID NO;
143 and a light chain variable region sequence of SEQ ID NO;
141.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
-
Citations
30 Claims
-
1. An immunoconjugate comprising a mutant interleukin-2 (IL-2) polypeptide and an immunoglobulin molecule that specifically binds Fibroblast Activation Protein (FAP), wherein said mutant IL-2 polypeptide comprises a mutant form of SEQ ID NO:
- 1, wherein said mutant form of SEQ ID NO;
1 comprises up to five amino acid substitutions of SEQ ID NO;
1, wherein said up to five amino acid substitutions comprise;
alanine at amino acid residue 42 of SEQ ID NO;
1, alanine at amino acid residue 45 of SEQ ID NO;
1, and glycine at amino acid residue 72 of SEQ ID NO;
1; andwherein said immunoglobulin molecule comprises a heavy chain variable region sequence of SEQ ID NO;
143 and a light chain variable region sequence of SEQ ID NO;
141. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- 1, wherein said mutant form of SEQ ID NO;
-
19. An immunoconjugate comprising a mutant interleukin-2 (IL-2) polypeptide and an immunoglobulin molecule that specifically binds Fibroblast Activation Protein (FAP),
wherein said mutant IL-2 polypeptide comprises the sequence of SEQ ID NO: - 19; and
wherein said immunoglobulin molecule comprises a heavy chain variable region sequence of SEQ ID NO;
143 and a light chain variable region sequence of SEQ ID NO;
141. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28)
- 19; and
-
29. An immunoconjugate comprising a mutant interleukin-2 (IL-2) polypeptide and an immunoglobulin molecule that specifically binds Fibroblast Activation Protein (FAP), wherein the immunoconjugate comprises a polypeptide sequence of SEQ ID NO:
- 299, a polypeptide sequence of SEQ ID NO;
297, and a polypeptide sequence of SEQ ID NO;
233. - View Dependent Claims (30)
- 299, a polypeptide sequence of SEQ ID NO;
Specification